Until recently, in addition to targeted therapy drugs, inhibitors of the immune checkpoint have shown prospective antitumor activity and have been approved in a series of cancers, of which the PD-1 inhibitors nivolumab and pembrolizumab have entered the top ten global drug sales in the first half of 2018 (Table 3). Here, PDCD1 is linked to cancer.